Description
LOXO-783 is an experimental drug currently being studied in clinical trials. It is being investigated as a potential treatment for certain types of solid tumors, including colorectal cancer, particularly in patients whose tumors have specific genetic changes. Specifically, trials have included patients with HER2 mutations or a specific type of PIK3CA mutation (H1047R). The main goal of the trials is to assess the safety, side effects, and potential effectiveness of LOXO-783. It is being tested in Phase 1 trials, which are early studies focused on safety and determining the right dose. The duration of participation in these trials can be long, potentially up to 3 years or more, depending on how the patient responds to the treatment.
Mechanism of Action
LOXO-783 is designed to target a specific protein involved in tumor growth and survival. The specific protein targeted by LOXO-783 is being characterized in clinical trials. It is believed to interfere with the signaling pathways that drive the growth of cancer cells, particularly those with certain genetic mutations like PIK3CA H1047R or HER2 mutations.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.